Biological
KITE-363
KITE-363 is a biological therapy with 4 clinical trials. Currently 2 active trials ongoing.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
2(50%)
Phase Distribution
Ph phase_1
3
75%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting2
Enrolling by invitation2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
recruiting250%
enrolling_by_invitation250%
Recent Activity
2 active trials
Showing 4 of 4
recruitingphase_1
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
NCT04989803
recruitingphase_1
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
NCT07304154
enrolling_by_invitationphase_1
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
NCT07038447
enrolling_by_invitation
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
NCT05041309
Clinical Trials (4)
Showing 4 of 4 trials
NCT04989803Phase 1
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
NCT07304154Phase 1
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
NCT07038447Phase 1
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
NCT05041309
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4